Author name: Ananta Kar

Twenty million Indians live with psoriasis, and for 80 per cent suffering moderate-to-severe plaque variants, the disease doesn’t merely affect skin—it devastates quality of life, relationships, and economic participation. Biologics have transformed what’s medically possible, delivering clearance rates unimaginable with conventional therapies, yet in India’s healthcare landscape, efficacy alone never determines what reaches patients. Cost […]

The biologics revolution—promising cures for cancer, genetic disorders, and autoimmune diseases—faces an unexpected executioner: not inadequate science, not manufacturing capacity, but regulatory bureaucracy. Whilst laboratories perfect cell cultures and purification cascades, drugs languish in approval pipelines for 12 to 18 months, inflating development costs by 30 to 50 per cent and postponing life-saving treatments by